Accolade (ACCD) has been on my watch list after I concluded early July that this was an interesting tech and healthcare offering when I looked at the investment thesis when the company went public.
The company has just reported its first-quarter results which were slightly better than expected, and while the current quarter looks a bit soft, Accolade guides for acceleration in the second half of the year. This makes the investment case compelling enough, certainly if shares might see a setback.
The Thesis
Accolade aims to empower people through expertise, empathy and